Alsevalimab is being evaluation as a promising therapeutic agent targeting human B7-H4. This therapy exhibits initial effectiveness in various tumor diseases by reducing B7-H4 protein's activity in cancerous https://alsevalimab010137.pointblog.net/alsevalimab-an-emerging-anti-b7-h4-immune-agent-in-investigation-94725620